Jim Simons
ADIL

Jim Simons’s Adial Pharmaceuticals ADIL Stock Holding History

Jim Simons’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,905
Closed -$48.1K – 3413
2024
Q4 		$48.1K Buy
+1,905
New +$49.6K ﹤0.01% 3396
2024
Q3 		– Sell
-1,374
Closed -$39.5K – 3494
2024
Q2 		$39.5K Sell
1,374
-670
-33% -$25.3K ﹤0.01% 3316
2024
Q1 		$68K Buy
2,044
+1,116
+120% +$41.8K ﹤0.01% 3435
2023
Q4 		$43K Buy
+928
New +$50.9K ﹤0.01% 3476
2023
Q3 		– Sell
-171
Closed -$22K – 3619
2023
Q2 		$22K Buy
171
+10
+6% +$1.81K ﹤0.01% 3755
2023
Q1 		$35K Sell
161
-242
-60% -$58.6K ﹤0.01% 3736
2022
Q4 		$54K Buy
403
+172
+74% +$30.1K ﹤0.01% 3781
2022
Q3 		$50K Sell
231
-40
-15% -$18K ﹤0.01% 3755
2022
Q2 		$227K Buy
271
+239
+747% +$216K ﹤0.01% 3593
2022
Q1 		$40K Buy
+32
New +$43.8K ﹤0.01% 3934
2021
Q1 		– Sell
-158
Closed -$168K – 3266
2020
Q4 		$168K Buy
158
+9
+6% +$10.6K ﹤0.01% 3173
2020
Q3 		$207K Buy
149
+82
+122% +$76.4K ﹤0.01% 3098
2020
Q2 		$58K Buy
+67
New +$60.5K ﹤0.01% 3329

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
RWML
RAFFA WEALTH MANAGEMENT, LLC Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jim Simons's ADIL Position: Q1 2025 in Review

Jim Simons sold out of Adial Pharmaceuticals (ADIL) in Q1 2025, closing a stake of 1,905 shares — an estimated $48.1K sold.

Jim Simons first reported a position in ADIL in Q2 2020 and held it in 13 quarters. The position peaked at $227K in Q2 2022. 13 funds tracked by Wall St. Rank hold ADIL as of Q1 2025.

  • Jim Simons reported no remaining Adial Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Jim Simons sold 1,905 Adial Pharmaceuticals shares in Q1 2025, an estimated $48.1K.
  • Jim Simons first reported a position in Adial Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • Jim Simons's Adial Pharmaceuticals position peaked at $227K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.